ArticleISRN pharmaceutics2012
Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept.
Article in ISRN pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 76 citations in OpenAlex.
- Mechanical performance of hybrid polymer-lipid vesicles with leaflet asymmetry engineered using microfluidics.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Synthesis of anisotropic gold nanoparticles in binary surfactant mixtures: a review on mechanisms of particle formation.RSC advances · 2025Review
- Review
- Microfluidic production of amiodarone loaded nanoparticles and application in drug repositioning in ovarian cancer.Scientific reports · 2024Article
- Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs.Pharmaceutics · 2023Article
- Customizing delivery nano-vehicles for precise brain tumor therapy.Journal of nanobiotechnology · 2023Review
- Hydroxyethylcellulose-Based Hydrogels Containing Liposomes Functionalized with Cell-Penetrating Peptides for Nasal Delivery of Insulin in the Treatment of Diabetes.Pharmaceutics · 2022Article
- Nanotechnology Based Approaches in Phage Therapy: Overcoming the Pharmacological Barriers.Frontiers in pharmacology · 2021Review
- Targeted Delivery of Doxorubicin Liposomes for Her-2+ Breast Cancer Treatment.AAPS PharmSciTech · 2020Article
- Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis.Frontiers in pharmacology · 2020Review
- The New Frontiers in Neurodegenerative Diseases Treatment: Liposomal-Based Strategies.Frontiers in bioengineering and biotechnology · 2020Review
- Development of Nanosome-Encapsulated Honokiol for Intravenous Therapy Against Experimental Autoimmune Encephalomyelitis.International journal of nanomedicine · 2020Article
- Soft-Nanoparticle Functionalization of Natural Hydrogels for Tissue Engineering Applications.Advanced healthcare materials · 2019Review
- Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications.Pharmaceutics · 2019Review
- Pharmacological Targeting of Pore-Forming Toxins as Adjunctive Therapy for Invasive Bacterial Infection.Toxins · 2018Review
- Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens.Advanced healthcare materials · 2018Review
- Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.International journal of nanomedicine · 2018Article
- Nanomaterials for the Capture and Therapeutic Targeting of Circulating Tumor Cells.Cellular and molecular bioengineering · 2017Review
- Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?Pharmaceutical research · 2016Review
- The nanomaterial toolkit for neuroengineering.Nano convergence · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing innovative delivery strategies remains an ongoing task to improve both efficacy and safety of drug-based therapy. Nanomedicine is now a promising field of investigation, rising high expectancies for treating various diseases such as malignancies. Putting drugs into liposome is an old story that started in the late 1960s. Because of the near-total biocompatibility of their lipidic bilayer, liposomes are less concerned with the safety issue related to the possible long-term accumulation in the body of most nanoobjects currently developed in nanomedicine. Additionally, novel techniques and recent efforts to achieve better stability (e.g., through sheddable coating), combined with a higher selectivity towards target cells (e.g., by anchoring monoclonal antibodies or incorporating phage fusion protein), make new liposomal drugs an attractive and challenging opportunity to improve clinical outcome in a variety of disease. This review covers the physicochemistry of liposomes and the recent technical improvements in the preparation of liposome-encapsulated drugs in regard to the scientific and medical stakes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.